ATE411987T1 - Dna-pk-inhibitoren - Google Patents

Dna-pk-inhibitoren

Info

Publication number: ATE411987T1
Authority: AT; Austria
Prior art keywords: optionally substituted; dna; ring; activity; compounds
Prior art date: 2001-08-14

Application number

AT02751439T

Other languages

English (en)

Inventor

Roger John Griffin

Bernard Thomas Golding

David Richard Newell

Hilary Alan Calvert

Nicola Jane Curtin

Ian Robert Hardcastle

Niall Morrison Barr Martin

Graeme Cameron Murray Smith

Laurent Jean Martin Rigoreau

Xiao-Ling Fan Cockcroft

Vincent Junior Ming-Lai Loh

Paul Workman

Florence Irene Raynaud

Bernard Paul Nutley

Original Assignee

Cancer Rec Tech Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-14

Filing date

2002-08-14

Publication date

2008-11-15

2002-08-14 Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd

2008-11-15 Application granted granted Critical

2008-11-15 Publication of ATE411987T1 publication Critical patent/ATE411987T1/de

Links

239000003112 inhibitor Substances 0.000 title 1
125000003118 aryl group Chemical group 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
230000000694 effects Effects 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000006701 (C1-C7) alkyl group Chemical group 0.000 abstract 1
102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 abstract 1
108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
229910052757 nitrogen Inorganic materials 0.000 abstract 1
125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
125000006413 ring segment Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/92—Naphthopyrans; Hydrogenated naphthopyrans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Engineering & Computer Science (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Oncology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Pyrane Compounds (AREA)

AT02751439T 2001-08-14 2002-08-14 Dna-pk-inhibitoren ATE411987T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB0119865.4A GB0119865D0 (en)	2001-08-14	2001-08-14	DNA-PK inhibitors

Publications (1)

Publication Number	Publication Date
ATE411987T1 true ATE411987T1 (de)	2008-11-15

Family

ID=9920420

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02751439T ATE411987T1 (de)	2001-08-14	2002-08-14	Dna-pk-inhibitoren

Country Status (22)

Country	Link
US (2)	US7226918B2 (de)
EP (1)	EP1417196B1 (de)
JP (1)	JP4332032B2 (de)
KR (1)	KR100905457B1 (de)
CN (1)	CN1279034C (de)
AT (1)	ATE411987T1 (de)
AU (1)	AU2002362385B2 (de)
BR (1)	BR0211889A (de)
CA (1)	CA2454023A1 (de)
CY (1)	CY1110269T1 (de)
DE (1)	DE60229531D1 (de)
DK (1)	DK1417196T3 (de)
ES (1)	ES2315377T3 (de)
GB (2)	GB0119865D0 (de)
HU (1)	HUP0401052A3 (de)
MX (1)	MXPA04000804A (de)
NO (1)	NO20040636L (de)
NZ (1)	NZ530909A (de)
PL (1)	PL367081A1 (de)
PT (1)	PT1417196E (de)
WO (1)	WO2003024949A1 (de)
ZA (1)	ZA200400237B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0119865D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119863D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
US7049313B2 (en)	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
AU2004228668B2 (en) *	2003-04-03	2011-10-27	Park Funding, Llc	PI-3 kinase inhibitor prodrugs
AU2004265149A1 (en)	2003-08-13	2005-02-24	Kudos Pharmaceuticals Limited	Aminopyrones and their use as ATM inhibitors
BRPI0515498A (pt) *	2004-09-20	2008-07-29	Kudos Pharm Ltd	inibidores de dna-pk
EP1848712A1 (de)	2005-02-09	2007-10-31	Kudos Pharmaceuticals Ltd	Atm-inhibitoren
AR053358A1 (es) *	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
US7909830B2 (en) *	2005-08-25	2011-03-22	Synthes Usa, Llc	Methods of spinal fixation and instrumentation
US20070049588A1 (en) *	2005-08-31	2007-03-01	Kudos Pharmaceuticals Limited	Atm inhibitor
EP2046768A1 (de) *	2006-07-18	2009-04-15	Kudos Pharmaceuticals Limited	Synthese von 2-amino-substituierten 4-oxo-4h-chromen-8-yltrifluormethansulfonsäureestern
CA2660560A1 (en) *	2006-08-16	2008-02-21	Boehringer Ingelheim International Gmbh	Pyrazine compounds, their use and methods of preparation
US20100130597A1 (en) *	2007-07-06	2010-05-27	The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service	Dna-pkcs modulates energy regulation and brain function
UY31232A1 (es) *	2007-07-19	2009-03-02		Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones
US20110130386A1 (en) *	2008-04-25	2011-06-02	Mark Frigerio	Dna-pk inhibitors
WO2010136778A1 (en) *	2009-05-29	2010-12-02	Kudos Pharmaceuticals Limited	Dibenzothiophene derivatives as dna- pk inhibitors
FR2951170B1 (fr) *	2009-10-09	2011-12-02	Sanofi Aventis	Nouveaux derives de 1h-pyrimidin-2-one, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
WO2011001115A1 (fr) *	2009-07-02	2011-01-06	Sanofi-Aventis	Nouveaux derives de 6-morpholin-4-yl-pyrimidin-4- ( 3h ) -one, leur preparation pharmaceutique comme inhibiteurs de phos phorylat i on d ' akt ( pkb )
HUE034503T2 (en)	2009-07-02	2018-02-28	Sanofi Sa	2,3-Dihydro-1-imidazo [1,2-a] pyrimidin-5-one derivatives, their preparation process and their use in medicine
FR2947548B1 (fr) *	2009-07-02	2012-05-18	Sanofi Aventis	Nouveaux derives de 1h-pyrimidin-2-one, leur preparation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
CN102482286B (zh)	2009-07-02	2015-07-15	赛诺菲	新型1,2,3,4-四氢嘧啶并{1,2-a}嘧啶-6-酮衍生物、其制备以及其医药用途
SG10201402867TA (en)	2009-07-02	2014-08-28	Sanofi Sa	Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
WO2011137428A1 (en) *	2010-04-30	2011-11-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods of treating hiv infection: inhibition of dna dependent protein kinase
DK2655375T3 (en)	2010-12-23	2015-03-09	Sanofi Sa	PYRIMIDINON DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF
US9133168B2 (en)	2010-12-28	2015-09-15	Sanofi	Pyrimidine derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors
UY34013A (es) *	2011-04-13	2012-11-30	Astrazeneca Ab	?compuestos de cromenona con actividad anti-tumoral?.
FR2992316A1 (fr)	2012-06-22	2013-12-27	Sanofi Sa	Derives de pyrimidinones, leur preparation et leur application en therapeutique
FR2992314B1 (fr)	2012-06-22	2015-10-16	Sanofi Sa	Nouveaux derives de 2,3-dihydro-1h-imidazo{1,2-a}pyrimidin-5-one et 1,2,3,4-tetrahydro-pyrimido{1,2-a}pyrimidin-6-one comportant une morpholine substituee, leur preparation et leur utilisation pharmaceutique
CN102977063A (zh) *	2012-11-26	2013-03-20	盛世泰科生物医药技术(苏州)有限公司	一种2-吗啡啉-8-苯基-4-苯并吡喃-4-酮的合成方法
ME03336B (de)	2013-03-12	2019-10-20	Vertex Pharma	Dna-pk-hemmer
JP6074043B2 (ja) *	2013-08-29	2017-02-01	富士フイルム株式会社	新規なモルホリン誘導体またはその塩
US11433047B2 (en) *	2015-10-09	2022-09-06	Neurotheryx Canada Ltd.	Pharmaceutical compositions comprising one or more pyrone compounds, and their use for treating inflammatory and neurodegenerative diseases
US20200101080A1 (en) *	2017-03-31	2020-04-02	Bioventures, Llc	Inhibitors of dna pk and uses thereof
EP3983542A2 (de)	2019-06-17	2022-04-20	CRISPR Therapeutics AG	Verfahren und zusammensetzungen für verbesserte homologie-gerichtete reparatur
CA3181340A1 (en)	2020-04-28	2021-11-04	Intellia Therapeutics, Inc.	Methods of in vitro cell delivery
WO2022133246A1 (en)	2020-12-17	2022-06-23	Vertex Pharmaceuticals Incorporated	Compositions and methods for editing beta-globin for treatment of hemaglobinopathies
IL307740A (en)	2021-04-17	2023-12-01	Intellia Therapeutics Inc	DNA-dependent protein kinase inhibitors and their compositions and uses
CN116903577B (zh) *	2023-07-03	2025-07-29	大连华一锂电科技有限公司	一种直接合成碳酸亚乙烯酯的方法
WO2025049481A1 (en)	2023-08-28	2025-03-06	Intellia Therapeutics, Inc.	Methods of editing an hla-a gene in vitro
WO2025181336A1 (en)	2024-03-01	2025-09-04	Cellectis Sa	Compositions and methods for hbb-editing in hspc
CN119118977B (zh) *	2024-08-23	2026-03-31	西北工业大学	一种γ-吡喃酮类化合物的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1303724A (de)	1969-05-14	1973-01-17
JPH0753725B2 (ja)	1987-10-08	1995-06-07	富山化学工業株式会社	４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
US5284856A (en)	1988-10-28	1994-02-08	Hoechst Aktiengesellschaft	Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
AU634994B2 (en) *	1988-12-21	1993-03-11	Pharmacia & Upjohn Company	Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
US5703075A (en)	1988-12-21	1997-12-30	Pharmacia & Upjohn Company	Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
JPH03215423A (ja)	1990-01-18	1991-09-20	Kyowa Hakko Kogyo Co Ltd	血管拡張剤
EP0525123B1 (de) *	1990-06-20	1997-09-17	PHARMACIA & UPJOHN COMPANY	Antiatherosklerotische und antithrombotische 1-benzopyran-4-on- und 2-amino-1,3-benzoxazin-4-on-derivate
US5252735A (en)	1990-06-29	1993-10-12	The Upjohn Company	Antiatherosclerotic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
ATE128128T1 (de) *	1990-06-29	1995-10-15	Upjohn Co	Antiatherosclerotische und antithrombotische 2- amino-6-phenyl-4h-pyran-4-one.
US5302613A (en)	1990-06-29	1994-04-12	The Upjohn Company	Antiatheroscleroic and antithrombotic 2-amino-6-phenyl-4H-pyran-4-ones
WO1994005283A1 (fr)	1992-09-02	1994-03-17	Kyowa Hakko Kogyo Co., Ltd.	Medicament anti-vih
EP0695547B1 (de)	1993-04-09	2001-08-08	Toyama Chemical Co., Ltd.	Immunomodulator, zelladhäsionsinhibitor und mittel zur behandlung und vorbeugung von autoimmunerkrankungen
US5378725A (en)	1993-07-19	1995-01-03	The Arizona Board Of Regents	Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
US5468773A (en)	1993-08-25	1995-11-21	Eli Lilly And Company	Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en)	1993-08-25	1996-04-02	Eli Lilly And Company	Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US5441947A (en)	1993-08-25	1995-08-15	Eli Lilly And Company	Methods of inhibiting vascular restenosis
CA2133815A1 (en)	1993-10-12	1995-04-13	Jeffrey Alan Dodge	Inhibition of phosphatidylinositol 3-kinase with viridin, demethoxyviridin, viridiol, demethoxyviridiol, virone, wortmannolone, and analogs thereof
US6632789B1 (en)	1994-04-29	2003-10-14	The United States Of America As Represented By The Secretary Of The Navy	Methods for modulating T cell responses by manipulating intracellular signal transduction
US5480906A (en)	1994-07-01	1996-01-02	Eli Lilly And Company	Stereochemical Wortmannin derivatives
GB9521987D0 (en)	1995-10-26	1996-01-03	Ludwig Inst Cancer Res	Phosphoinositide 3-kinase modulators
US5733920A (en)	1995-10-31	1998-03-31	Mitotix, Inc.	Inhibitors of cyclin dependent kinases
AU1461197A (en)	1995-11-16	1997-06-05	Icos Corporation	Cell cycle checkpoint pik-related kinase materials and methods
GB2302021A (en)	1996-10-16	1997-01-08	Lilly Co Eli	Inhibiting bone loss or resorption
WO1998055602A1 (en)	1997-06-06	1998-12-10	Mayo Foundation For Medical Education And Research	Screening for phosphatidylinositol related-kinase inhibitors
WO1998056391A1 (en)	1997-06-13	1998-12-17	President And Fellows Of Harvard College	Methods for treating human cancers
FR2776291B1 (fr)	1998-03-18	2000-06-16	Pf Medicament	Nouveaux derives bis-benzamides, leur procede de fabrication, les compositions pharmaceutiques les contenant et leur utilisation comme medicament
US6348311B1 (en)	1999-02-10	2002-02-19	St. Jude Childre's Research Hospital	ATM kinase modulation for screening and therapies
US6387640B1 (en)	1999-02-10	2002-05-14	St. Jude Children's Research Hospital	ATM kinase modulation for screening and therapies
CN1891693A (zh) *	2000-01-24	2007-01-10	基纳西亚股份有限公司	用于治疗的吗啉代基取代的化合物
JP2004501191A (ja) *	2000-06-28	2004-01-15	テバ　ファーマシューティカル　インダストリーズ　リミティド	カルベジロール
WO2002020500A2 (en)	2000-09-01	2002-03-14	Icos Corporation	Materials and methods to potentiate cancer treatment
DE60203260T2 (de)	2001-01-16	2006-02-02	Glaxo Group Ltd., Greenford	Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
GB0119863D0 (en) *	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
GB0119865D0 (en)	2001-08-14	2001-10-10	Cancer Res Campaign Tech	DNA-PK inhibitors
AU2002357667A1 (en)	2001-10-24	2003-05-06	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
WO2003035618A2 (en)	2001-10-24	2003-05-01	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
US7049313B2 (en)	2002-02-25	2006-05-23	Kudos Pharmaceuticals Ltd.	ATM inhibitors
BR0307944A (pt)	2002-02-25	2005-02-01	Kudos Pharm Ltd	Piranonas úteis como inibidores de atm
DE60335359D1 (de)	2002-04-30	2011-01-27	Kudos Pharm Ltd	Phthalazinonderivate
AU2004265149A1 (en) *	2003-08-13	2005-02-24	Kudos Pharmaceuticals Limited	Aminopyrones and their use as ATM inhibitors
BRPI0515498A (pt) *	2004-09-20	2008-07-29	Kudos Pharm Ltd	inibidores de dna-pk
EP1848712A1 (de)	2005-02-09	2007-10-31	Kudos Pharmaceuticals Ltd	Atm-inhibitoren
AR053358A1 (es) *	2005-04-15	2007-05-02	Cancer Rec Tech Ltd	Inhibidores de adn - pk
UY31232A1 (es) *	2007-07-19	2009-03-02		Compuestos derivados de dibenzotifenilamino-cromen-4-onas activas sustituidas y sus isomeros y aplicaciones

2001
- 2001-08-14 GB GBGB0119865.4A patent/GB0119865D0/en not_active Ceased
2002
- 2002-08-14 NZ NZ530909A patent/NZ530909A/en not_active IP Right Cessation
- 2002-08-14 CN CNB028159780A patent/CN1279034C/zh not_active Expired - Fee Related
- 2002-08-14 HU HU0401052A patent/HUP0401052A3/hu unknown
- 2002-08-14 WO PCT/GB2002/003781 patent/WO2003024949A1/en not_active Ceased
- 2002-08-14 US US10/486,816 patent/US7226918B2/en not_active Expired - Lifetime
- 2002-08-14 AU AU2002362385A patent/AU2002362385B2/en not_active Ceased
- 2002-08-14 DE DE60229531T patent/DE60229531D1/de not_active Expired - Lifetime
- 2002-08-14 AT AT02751439T patent/ATE411987T1/de active
- 2002-08-14 MX MXPA04000804A patent/MXPA04000804A/es active IP Right Grant
- 2002-08-14 CA CA002454023A patent/CA2454023A1/en not_active Abandoned
- 2002-08-14 ES ES02751439T patent/ES2315377T3/es not_active Expired - Lifetime
- 2002-08-14 JP JP2003528797A patent/JP4332032B2/ja not_active Expired - Fee Related
- 2002-08-14 BR BR0211889-0A patent/BR0211889A/pt not_active IP Right Cessation
- 2002-08-14 DK DK02751439T patent/DK1417196T3/da active
- 2002-08-14 PT PT02751439T patent/PT1417196E/pt unknown
- 2002-08-14 KR KR1020047002182A patent/KR100905457B1/ko not_active Expired - Fee Related
- 2002-08-14 GB GB0401411A patent/GB2393653B/en not_active Expired - Fee Related
- 2002-08-14 EP EP02751439A patent/EP1417196B1/de not_active Expired - Lifetime
- 2002-08-14 PL PL02367081A patent/PL367081A1/xx not_active Application Discontinuation
2004
- 2004-01-13 ZA ZA200400237A patent/ZA200400237B/xx unknown
- 2004-02-12 NO NO20040636A patent/NO20040636L/no not_active Application Discontinuation
2007
- 2007-06-05 US US11/758,332 patent/US7674823B2/en not_active Expired - Fee Related
2009
- 2009-01-14 CY CY20091100039T patent/CY1110269T1/el unknown

Also Published As

Publication number	Publication date
US7226918B2 (en)	2007-06-05
ZA200400237B (en)	2004-08-18
GB0119865D0 (en)	2001-10-10
ES2315377T3 (es)	2009-04-01
JP2005503414A (ja)	2005-02-03
AU2002362385B2 (en)	2008-07-31
GB2393653B (en)	2005-02-02
US20070238729A1 (en)	2007-10-11
HUP0401052A3 (en)	2007-05-29
HK1070368A1 (en)	2005-06-17
WO2003024949A1 (en)	2003-03-27
PL367081A1 (en)	2005-02-21
GB0401411D0 (en)	2004-02-25
KR100905457B1 (ko)	2009-07-02
DE60229531D1 (de)	2008-12-04
US20040192687A1 (en)	2004-09-30
CN1543457A (zh)	2004-11-03
MXPA04000804A (es)	2004-06-03
NO20040636L (no)	2004-04-02
KR20040032152A (ko)	2004-04-14
CA2454023A1 (en)	2003-03-27
BR0211889A (pt)	2004-09-21
US7674823B2 (en)	2010-03-09
EP1417196A1 (de)	2004-05-12
EP1417196B1 (de)	2008-10-22
CY1110269T1 (el)	2015-01-14
JP4332032B2 (ja)	2009-09-16
DK1417196T3 (da)	2009-03-02
CN1279034C (zh)	2006-10-11
GB2393653A (en)	2004-04-07
PT1417196E (pt)	2009-01-02
HUP0401052A2 (hu)	2004-09-28
NZ530909A (en)	2005-10-28

Legal Events

Date

Code

Title

Description

2009-06-15

UEP

Publication of translation of european patent specification

Ref document number: 1417196

Country of ref document: EP

Publication	Publication Date	Title
DE60229531D1 (de)	2008-12-04	Dna-pk-inhibitoren
TW200616986A (en)	2006-06-01	DNA-pk inhibitors
TW200605883A (en)	2006-02-16	Condensed heterocycle derivative having HCV inhibitory activity
TW200638938A (en)	2006-11-16	ATM inhibitors
DE602004026071D1 (de)	2010-04-29	Aminopyrone und ihre verwendung als atm inhibitoren
NO20004485L (no)	2000-09-08	Sykloalkenderivater, deres fremstilling og anvendelse
HUP0401303A2 (hu)	2004-12-28	Fungicid hatással rendelkező jódbenzopirán-4-on-származékok, előállításuk, alkalmazásuk és ilyeneket tartalmazó készítmények
EP1258252A4 (de)	2005-11-02	Inhibitoren der integrinexpression
WO2006055922A8 (en)	2007-03-15	Anthranilamide insecticides
AP1541A (en)	2006-01-11	New thiadazoles and oxadiazoles and their use as phosphodiesterase - 7 inhibitors.
TWI265164B (en)	2006-11-01	3-substituted-4-pyrimidone derivatives
HUP0402025A2 (hu)	2005-02-28	Új benzofenon származékok és sóik és alkalmazásuk
ATE281430T1 (de)	2004-11-15	Anilin-derivate als stickstoffmonoxid synthase- inhibitoren
HUP0004477A2 (hu)	2001-02-28	Herbicid hatású 3-(1,2-benzizotiazol- vagy-izoxazol-5-il)-csoporttal helyettesített pirimidinszármazékok, intermedierjeik, előállításuk és alkalmazásuk
DK1847534T3 (da)	2011-08-29	Thiadiazolin-derivater til behandling af kræft
GB0119863D0 (en)	2001-10-10	DNA-PK inhibitors
YU18404A (sh)	2006-08-17	Hemijska jedinjenja
ATE449773T1 (de)	2009-12-15	Homomorpholinoxazolidinone als antibakterielle mittel
TH76092A (th)	2006-03-02	เฮเทอโรแอริล เฟนิลยูเรีย
TW200721977A (en)	2007-06-16	Anthranilamide insecticides
UY26949A1 (es)	2002-06-20	Nuevos tidiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa - 7
TH61861A3 (th)	2004-05-04	4-ออกโซ-1,4-ไดไฮโดร-3-ควิโนลีนคาร์บอกซามีดที่เป็นตัวกระทำต้านเชื้อไวรัส